News

Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal Encouraging traction in Ryaltris across focus markets * Glenmark Pharma (GNP)’s 1QFY24 operational performance beat our estimates, led by strong performance in EU/ROW markets. Lower R&D spending resulted in margin expansion YoY as well as QoQ. * We raise our earnings estimates by 4%/3% for FY24/FY25, factoring in strong off-take in the respiratory portfolio in EU, increased traction in Ryaltris across focus markets, and healthy traction in the consumer care segment within the ...
Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal
Neutral Glenmark Pharma Ltd For Target Rs. 780 - Motilal Oswal
Source: Motilal Oswal Financial Services
15/08/2023 11:17:38 AM
Glenmark Pharmaceuticals gains on partnering with OMRON Healthcare India Glenmark Pharmaceuticals is currently trading at Rs. 794.70, up by 2.75 points or 0.35% from its previous closing of Rs. 791.95 on the BSE. The scrip opened at Rs. 798.85 and has touched a high and low of Rs. 798.90 and Rs. 784.05 respectively. So far 9683 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 832.90 on 27-Jul-2023 and a 52 week low of Rs. 361.70 on 29-Aug-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals gains on partnering with OMRON Healthcare India
Glenmark Pharmaceuticals gains on partnering with OMRON Healthcare India
Source: Accord Fintech
4/08/2023 11:45:32 AM
Glenmark Pharmaceuticals gains on getting USFDA`s final approval for Saxagliptin Tablets Glenmark Pharmaceuticals is currently trading at Rs. 794.40, up by 6.20 points or 0.79% from its previous closing of Rs. 788.20 on the BSE. The scrip opened at Rs. 799.55 and has touched a high and low of Rs. 799.55 and Rs. 790.00 respectively. So far 3085 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 832.90 on 27-Jul-2023 and a 52 week low of Rs. 361.70 on 29-Aug-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals gains on getting USFDA`s final approval for Saxagliptin Tablets
Glenmark Pharmaceuticals gains on getting USFDA`s final approval for Saxagliptin Tablets
Source: Accord Fintech
1/08/2023 10:17:50 AM
Buy Glenmark Pharmaceuticals Ltd Target Rs.760 - Sushil Finance We have coverage on Glenmark Pharmaceuticals Ltd with a BUY rating on stock. Since our report, the stock has posted a high of Rs.736 today. With the recent run-up in the share price (19% return), we are now changing our rating on the stock to Neutral and recommend our investors to start booking profits.   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://www.sushilfinance.com/Disclamier/disclaimer Member : BSE/ NSE/ MSE...
Buy Glenmark Pharmaceuticals Ltd Target Rs.760 - Sushil Finance
Buy Glenmark Pharmaceuticals Ltd Target Rs.760 - Sushil Finance
Source: Sushil Finance Ltd
30/07/2023 3:15:05 PM
Glenmark Pharmaceuticals falls after USFDA issues warning letter to Monroe facility Glenmark Pharmaceuticals is currently trading at Rs. 625.05, down by 17.65 points or 2.75% from its previous closing of Rs. 642.70 on the BSE. The scrip opened at Rs. 637.10 and has touched a high and low of Rs. 641.00 and Rs. 622.05 respectively. So far 24274 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 682.00 on 08-Jun-2023 and a 52 week low of Rs. 351.40 on 23-Jun-2022. Last one week high and low of the sc...
Glenmark Pharmaceuticals falls after USFDA issues warning letter to Monroe facility
Glenmark Pharmaceuticals falls after USFDA issues warning letter to Monroe facility
Source: Accord Fintech
22/06/2023 2:25:22 PM
Stock Picks : JSW Steel Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct JSW Steel Ltd Buy Reliance Industries Ltd @712-713 CMP 712.85; Target 723.00; Stop Loss 707.20   Glenmark Pharmaceuticals Ltd Buy ZEE Entertainment Ltd @631-632 CMP 631.50; Target 641.00; Stop Loss 626.40     To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registrati...
Stock Picks : JSW Steel Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct
Stock Picks : JSW Steel Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct
Source: ICICI Direct
7/06/2023 10:37:07 AM
Reduce Glenmark Pharmaceuticals Ltd For Target Rs.575- ICICI Securities Ryaltris drives traction across markets Glenmark Pharma’s (Glenmark) Q4FY23 revenue growth of 12% YoY was driven by launch of Rylatris across the UK, Asia and RoW markets. Nevertheless, the company’s gross margins contracted 119bps YoY due to cost pressures in India and base price erosion in the US. Traction in Rylatris should aid growth and better margins across key export markets while brand divestments (Razel and derma brands) may taper down India growth. Gross debt surged 1...
Reduce Glenmark Pharmaceuticals Ltd For Target Rs.575- ICICI Securities
Reduce Glenmark Pharmaceuticals Ltd For Target Rs.575- ICICI Securities
Source: ICICI Securities Ltd
6/06/2023 12:27:12 PM
Stock Picks : Reliance Industries Ltd and Glenmark Ltd By ICICI Direct Reliance Industries Ltd Buy Reliance Industries Ltd @2462-2466 CMP CMP 2463.25; Target 2498.00; Stop Loss 2447.80   Glenmark Ltd Buy Glenmark Ltd @608-610 CMP CMP 609.60; Target 619.80; Stop Loss 604.70   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration...
Stock Picks : Reliance Industries Ltd and Glenmark Ltd By ICICI Direct
Stock Picks : Reliance Industries Ltd and Glenmark Ltd By ICICI Direct
Source: ICICI Direct
2/06/2023 11:05:56 AM
Glenmark Pharmaceuticals trades higher on the BSE Glenmark Pharmaceuticals is currently trading at Rs. 612.70, up by 3.95 points or 0.65% from its previous closing of Rs. 608.75 on the BSE. The scrip opened at Rs. 608.75 and has touched a high and low of Rs. 614.75 and Rs. 607.65 respectively. So far 27641 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 617.70 on 15-May-2023 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals trades higher on the BSE
Glenmark Pharmaceuticals trades higher on the BSE
Source: Accord Fintech
16/05/2023 1:13:41 PM
Glenmark Pharmaceuticals rises on incorporating wholly-owned subsidiary Glenmark Pharmaceuticals is currently trading at Rs. 613.55, up by 0.85 points or 0.14% from its previous closing of Rs. 612.70 on the BSE. The scrip opened at Rs. 613.00 and has touched a high and low of Rs. 617.70 and Rs. 608.90 respectively. So far 19882 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 615.80 on 15-May-2023 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals rises on incorporating wholly-owned subsidiary
Glenmark Pharmaceuticals rises on incorporating wholly-owned subsidiary
Source: Accord Fintech
15/05/2023 11:07:59 AM
Glenmark Pharmaceuticals trades higher on the BSE Glenmark Pharmaceuticals is currently trading at Rs. 520.25, up by 1.90 points or 0.37% from its previous closing of Rs. 518.35 on the BSE. The scrip opened at Rs. 517.95 and has touched a high and low of Rs. 522.50 and Rs. 516.65 respectively. So far 57714 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 522.50 on 26-Apr-2023 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals trades higher on the BSE
Glenmark Pharmaceuticals trades higher on the BSE
Source: Accord Fintech
26/04/2023 2:44:50 PM
Glenmark Pharmaceuticals rises as its arm gets USFDA`s approval for GRC 54276 Glenmark Pharmaceuticals is currently trading at Rs. 435.60, up by 3.00 points or 0.69% from its previous closing of Rs. 432.60 on the BSE. The scrip opened at Rs. 440.10 and has touched a high and low of Rs. 440.10 and Rs. 433.15 respectively. So far 15122 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.15 on 11-Apr-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals rises as its arm gets USFDA`s approval for GRC 54276
Glenmark Pharmaceuticals rises as its arm gets USFDA`s approval for GRC 54276
Source: Accord Fintech
17/03/2023 12:06:25 PM
Glenmark Pharmaceuticals rises on inking pact with Cediprof Glenmark Pharmaceuticals is currently trading at Rs. 426.30, up by 0.50 points or 0.12% from its previous closing of Rs. 425.80 on the BSE. The scrip opened at Rs. 423.70 and has touched a high and low of Rs. 429.15 and Rs. 423.70 respectively. So far 5231 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 487.15 on 11-Apr-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals rises on inking pact with Cediprof
Glenmark Pharmaceuticals rises on inking pact with Cediprof
Source: Accord Fintech
9/03/2023 11:35:14 AM
Buy Glenmark Pharmaceuticals Ltd Target Rs.474 - Religare Broking * Glenmark is among the prominent name within the pharma space and it rewards handsomely to traders during reversals. In line with past instances, it surged sharply from March 2020 low i.e. around 157 to 677.47 levels by September 2021. * It witnessed a year-long corrective phase after that surge and again retraced to the monthly support zone around 350 levels. After spending nearly six months within the 350-410 zone, it has finally seen a breakout from the same now. * The recent buoyan...
Buy Glenmark Pharmaceuticals Ltd Target Rs.474 - Religare Broking
Buy Glenmark Pharmaceuticals Ltd Target Rs.474 - Religare Broking
Source: Religare Broking Ltd
3/03/2023 10:59:22 AM
Glenmark Pharmaceuticals rises as its arm gets second tentative approval for Saxagliptin Tablets Glenmark Pharmaceuticals is currently trading at Rs. 439.85, up by 4.70 points or 1.08% from its previous closing of Rs. 435.15 on the BSE. The scrip opened at Rs. 429.10 and has touched a high and low of Rs. 440.40 and Rs. 429.10 respectively. So far 9131 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 497.60 on 17-Feb-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals rises as its arm gets second tentative approval for Saxagliptin Tablets
Glenmark Pharmaceuticals rises as its arm gets second tentative approval for Saxagliptin Tablets
Source: Accord Fintech
17/02/2023 11:27:54 AM
Glenmark Pharmaceuticals soars on reporting 21% rise in Q3 consolidated net profit Glenmark Pharmaceuticals is currently trading at Rs. 415.00, up by 15.15 points or 3.79% from its previous closing of Rs. 399.85 on the BSE. The scrip opened at Rs. 410.00 and has touched a high and low of Rs. 422.35 and Rs. 405.20 respectively. So far 74155 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 498.40 on 11-Feb-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scri...
Glenmark Pharmaceuticals soars on reporting 21% rise in Q3 consolidated net profit
Glenmark Pharmaceuticals soars on reporting 21% rise in Q3 consolidated net profit
Source: Accord Fintech
13/02/2023 12:14:05 PM
Glenmark Pharmaceuticals trades higher on entering into agreement with Eris Oaknet Healthcare Glenmark Pharmaceuticals is currently trading at Rs. 421.00, up by 4.55 points or 1.09% from its previous closing of Rs. 416.45 on the BSE. The scrip opened at Rs. 420.00 and has touched a high and low of Rs. 421.75 and Rs. 414.70 respectively. So far 7135 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 521.35 on 18-Jan-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals trades higher on entering into agreement with Eris Oaknet Healthcare
Glenmark Pharmaceuticals trades higher on entering into agreement with Eris Oaknet Healthcare
Source: Accord Fintech
18/01/2023 11:16:02 AM
Key Stock News: Carlyle Group , Byju's,, Glenmark Pharma, TCS, Adani Enterprises - ARETE Securities Carlyle Group acquires majority stake in beauty brand VLCC for $300 million Private-equity firm Carlyle Group has acquired a majority stake in Indian beauty care and wellness solutions provider VLCC for around $300 million, two sources told Reuters on Tuesday The equity for the transaction will come from funds managed and advised by entities affiliated with Carlyle Asia Partners, Carlyle said in a statement, without specifying a deal value. Byju's seeks more time from lenders to ...
Key Stock News: Carlyle Group , Byju's,, Glenmark Pharma, TCS, Adani Enterprises - ARETE Securities
Key Stock News: Carlyle Group , Byju's,, Glenmark Pharma, TCS, Adani Enterprises - ARETE Securities
Source: ARETE Securities Ltd
11/01/2023 9:25:19 AM
Glenmark Pharma rises as its arm launches Bumetanide Injection Glenmark Pharmaceuticals is currently trading at Rs. 430.80, up by 4.05 points or 0.95% from its previous closing of Rs. 426.75 on the BSE. The scrip opened at Rs. 427.90 and has touched a high and low of Rs. 430.80 and Rs. 426.80 respectively. So far 1657 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 528.05 on 14-Jan-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharma rises as its arm launches Bumetanide Injection
Glenmark Pharma rises as its arm launches Bumetanide Injection
Source: Accord Fintech
10/01/2023 9:39:19 AM
Glenmark is the first company to launch a Triple FDC of Teneligliptin + Pioglitazone + Metformin Glenmark is the first company to launch in India a Triple FDC of Teneligliptin + Pioglitazone + Metformin for Adults with Type 2 Diabetes & High Insulin Resistance - This Fixed-Dose Combination (FDC) of Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) SRunder the brand name Zita®-PioMet. - The noveltriple FDC will help improve glycemic control among adults with High HbA1ci and high insulin resistance, those whose diabetes is uncontrolled by metformin alone...
Glenmark is the first company to launch a Triple FDC of Teneligliptin + Pioglitazone + Metformin
Glenmark is the first company to launch a Triple FDC of Teneligliptin + Pioglitazone + Metformin
Source: PR Agency
22/12/2022 11:37:58 AM
Key Stock News: IIFL fintech , M3M India, Vedanta, Byju's, Glenmark Pharma, Dabur - ARETE Securities IIFL fintech fund picks up 16% in Insurance Samadhan for $2 million The IIFL Group's early-stage investment vehicle, IIFL Fintech Fund, has invested USD 2 million (around Rs 16.5 crore) in insurance technology startup Insurance Samadhan for a 16 per cent stake, valuing the platform at around USD 13 million (around Rs 107 crore). The startup also received another USD 1 million from other investors in the series-A round. This is IIFL fintech fund's 10th investment and first in the...
Key Stock News: IIFL fintech , M3M India, Vedanta, Byju's, Glenmark Pharma, Dabur - ARETE Securities
Key Stock News: IIFL fintech , M3M India, Vedanta, Byju's, Glenmark Pharma, Dabur - ARETE Securities
Source: ARETE Securities Ltd
22/12/2022 9:59:11 AM
Glenmark Pharmaceuticals rises on launching first triple FDC Teneligliptin with Pioglitazone and Metformin Glenmark Pharmaceuticals is currently trading at Rs. 415.50, up by 6.30 points or 1.54% from its previous closing of Rs. 409.20 on the BSE. The scrip opened at Rs. 411.45 and has touched a high and low of Rs. 417.55 and Rs. 409.80 respectively. So far 3745 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 533.95 on 03-Jan-2022 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals rises on launching first triple FDC Teneligliptin with Pioglitazone and Metformin
Glenmark Pharmaceuticals rises on launching first triple FDC Teneligliptin with Pioglitazone and Metformin
Source: Accord Fintech
21/12/2022 10:37:19 AM
Nutral Glenmark Pharmaceuticals Ltd For Target Rs.420 - Motilal Oswal Financial Services Working on many fronts to better outlook and return ratios We attended GNP’s investor day to understand the management’s strategies across major business segments over the next four-to-five years. * GNP aims to boost RoCE (EBIT/capital employed) to 22% by FY27 (from 17% in FY22), with an increased share of the branded generics business, controlled R&D spends towards the NCE portfolio, and sustained improvement in operating leverage. * It also aims to have zero net deb...
Nutral Glenmark Pharmaceuticals Ltd For Target Rs.420 - Motilal Oswal Financial Services
Nutral Glenmark Pharmaceuticals Ltd For Target Rs.420 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
28/11/2022 12:48:51 PM
Glenmark Pharmaceuticals jumps on reaching settlement agreement with Pfizer for Axitinib Tablets Glenmark Pharmaceuticals is currently trading at Rs. 419.60, up by 8.05 points or 1.96% from its previous closing of Rs. 411.55 on the BSE. The scrip opened at Rs. 412.05 and has touched a high and low of Rs. 420.55 and Rs. 412.05 respectively. So far 12439 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals jumps on reaching settlement agreement with Pfizer for Axitinib Tablets
Glenmark Pharmaceuticals jumps on reaching settlement agreement with Pfizer for Axitinib Tablets
Source: IANS
22/11/2022 1:52:07 PM
Glenmark Pharmaceuticals surges on reporting rise in Q2 consolidated net profit Glenmark Pharmaceuticals is currently trading at Rs. 429.10, up by 14.95 points or 3.61% from its previous closing of Rs. 414.15 on the BSE. The scrip opened at Rs. 417.00 and has touched a high and low of Rs. 434.65 and Rs. 417.00 respectively. So far 193627 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scr...
Glenmark Pharmaceuticals surges on reporting rise in Q2 consolidated net profit
Glenmark Pharmaceuticals surges on reporting rise in Q2 consolidated net profit
Source: Accord Fintech
14/11/2022 3:22:16 PM
Glenmark Pharmaceuticals rises on getting USFDA`s nod for Sodium Phenylbutyrate Tablets Glenmark Pharmaceuticals is currently trading at Rs. 418.30, up by 5.10 points or 1.23% from its previous closing of Rs. 404.40 on the BSE. The scrip opened at Rs. 412.15 and has touched a high and low of Rs. 418.00 and Rs. 412.15 respectively. So far 8167 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark Pharmaceuticals rises on getting USFDA`s nod for Sodium Phenylbutyrate Tablets
Glenmark Pharmaceuticals rises on getting USFDA`s nod for Sodium Phenylbutyrate Tablets
Source: Accord Fintech
2/11/2022 10:10:40 AM
Glenmark Pharma surges as its arm launches Fingolimod Capsules in US Glenmark Pharmaceuticals is currently trading at Rs. 413.00, up by 8.60 points or 2.13% from its previous closing of Rs. 404.40 on the BSE. The scrip opened at Rs. 407.10 and has touched a high and low of Rs. 415.75 and Rs. 406.30 respectively. So far 42590 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharma surges as its arm launches Fingolimod Capsules in US
Glenmark Pharma surges as its arm launches Fingolimod Capsules in US
Source: Accord Fintech
1/11/2022 10:29:46 AM
Glenmark gains on becoming first company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination Glenmark Pharmaceuticals is currently trading at Rs. 398.00, up by 2.60 points or 0.66% from its previous closing of Rs. 395.40 on the BSE. The scrip opened at Rs. 396.60 and has touched a high and low of Rs. 403.00 and Rs. 392.65 respectively. So far 21781 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark gains on becoming first company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination
Glenmark gains on becoming first company in India to launch Teneligliptin + Dapagliflozin Fixed Dose Combination
Source: Accord Fintech
20/10/2022 3:31:10 PM
Glenmark Pharma inches up after its arm launches Ryaltris seasonal allergic rhinitis nasal spray in US Glenmark Pharmaceuticals is currently trading at Rs. 371.40, up by 0.10 points or 0.03% from its previous closing of Rs. 371.30 on the BSE. The scrip opened at Rs. 372.00 and has touched a high and low of Rs. 374.90 and Rs. 371.10 respectively. So far 27760 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 551.50 on 26-Nov-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharma inches up after its arm launches Ryaltris seasonal allergic rhinitis nasal spray in US
Glenmark Pharma inches up after its arm launches Ryaltris seasonal allergic rhinitis nasal spray in US
Source: Accord Fintech
1/09/2022 12:27:19 PM
Hold GSK Pharma Ltd Rs.1,462 - ICICI Securities Ltd Analyst call highlights GlaxoSmithKline Pharmaceuticals (GSKP) held an analyst meet to discuss the company’s performance. Highlights: * Company believes its key brands and therapies would continue to grow. It has been able to maintain its market share in key brands and expects to improve on it gradually. GSKP intends to provide healthcare support to 2.5bn people worldwide over the next 10 years, wherein India would be an integral part. * Vaccines remains an important growth are...
Hold GSK Pharma Ltd Rs.1,462 - ICICI Securities Ltd
Hold GSK Pharma Ltd Rs.1,462 - ICICI Securities Ltd
Source: ICICI Securities Ltd
26/08/2022 9:15:25 AM
Hold GSK Pharma Ltd Rs.1,462 - ICICI Direct Analyst call highlights GlaxoSmithKline Pharmaceuticals (GSKP) held an analyst meet to discuss the company’s performance. Highlights: * Company believes its key brands and therapies would continue to grow. It has been able to maintain its market share in key brands and expects to improve on it gradually. GSKP intends to provide healthcare support to 2.5bn people worldwide over the next 10 years, wherein India would be an integral part. * Vaccines remains an important growth are...
Hold GSK Pharma Ltd Rs.1,462 - ICICI Direct
Hold GSK Pharma Ltd Rs.1,462 - ICICI Direct
Source: ICICI Direct
24/08/2022 2:15:17 PM
Buy Glenmark Pharmaceuticals Ltd Target Rs.622 - Sushil Finance Highlights from the Quarter (Q1 FY23) Consolidated sales for the quarter were at Rs.2,777.3 cr recording degrowth of about 5.7% yoy. Excluding the global sales of COVID-related products in the Q1FY22, the yoy growth in the base business was at 10.4%. The Company launched seven new products during the quarter, including Indamet (the first company in India to launch) for the treatment of uncontrolled asthma. It expects a mid-teens growth for FY23, with good launches in respiratory and diabet...
Buy Glenmark Pharmaceuticals Ltd Target Rs.622 - Sushil Finance
Buy Glenmark Pharmaceuticals Ltd Target Rs.622 - Sushil Finance
Source: Sushil Finance
20/08/2022 9:29:05 AM
Hold Glenmark Pharmaceuticals For Target Rs.440 ICICI Direct Ltd Weak margins; US base business under pressure About the stock: Glenmark’s business is separated into three entitie *Glenmark Pharmaceuticals for building a global generic, specialty and OTC business in therapy areas of dermatology, respiratory, oncology among others *Glenmark Life Sciences for manufacturing and marketing APIs *Innovation new company (ICHNOS) to focus on discovery and development of novel, first?in?class treatments in the therapeutic areas of immunology, onco...
Hold Glenmark Pharmaceuticals For Target Rs.440 ICICI Direct Ltd
Hold Glenmark Pharmaceuticals For Target Rs.440 ICICI Direct Ltd
Source: ICICI Direct Ltd
17/08/2022 11:10:28 AM
Glenmark Pharma rises on getting USFDA nod for Norethindrone Acetate and Ethinyl Estradiol Capsules Glenmark Pharma is currently trading at Rs. 381.15, up by 1.25 points or 0.33% from its previous closing of Rs. 379.90 on the BSE. The scrip opened at Rs. 382.50 and has touched a high and low of Rs. 383.00 and Rs. 375.20 respectively. So far 55247 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 618.00 on 02-Aug-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip stood at...
Glenmark Pharma rises on getting USFDA nod for Norethindrone Acetate and Ethinyl Estradiol Capsules
Glenmark Pharma rises on getting USFDA nod for Norethindrone Acetate and Ethinyl Estradiol Capsules
Source: Accord Fintech
29/07/2022 4:05:31 PM
Glenmark Pharma`s arm recalls 98,307 packs of Mometasone Furoate Topical Solution Glenmark Pharmaceuticals’ fully owned subsidiary -- Glenmark Pharmaceuticals Inc., USA (Glenmark) is recalling 98,307 packs of Mometasone Furoate Topical Solution, a medication used to treat skin conditions such as eczema, psoriasis, allergies, and rash. The company is recalling the lot, which rolled out from the company's Baddi (Himachal Pradesh) plant, due to Defective Container. The company initiated the nationwide recall, which the US health regulator classified as Class III,...
Glenmark Pharma`s arm recalls 98,307 packs of Mometasone Furoate Topical Solution
Glenmark Pharma`s arm recalls 98,307 packs of Mometasone Furoate Topical Solution
Source: Accord Fintech
25/07/2022 10:06:42 AM
Glenmark Pharmaceuticals launches `Minym Gel` for acne treatment Glenmark Pharmaceuticals has launched India’s first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name Minym. This is a potent antibacterial gel which exerts a strong anti-inflammatory action It also offers the lowest MIC90 (minimum Inhibitory Concentration at which it stops/prevents visible growth of 90% of isolates of bacteria) compared to the available topical antibacterial formulations. Topical antibacterial formulations are some of the ...
Glenmark Pharmaceuticals launches `Minym Gel` for acne treatment
Glenmark Pharmaceuticals launches `Minym Gel` for acne treatment
Source: Accord Fintech
11/07/2022 10:05:27 AM
Glenmark rises on launching Sitagliptin and its FDCs for adults with Type 2 Diabetes in India Glenmark Pharmaceuticals is currently trading at Rs. 389.45, up by 0.55 points or 0.14% from its previous closing of Rs. 388.90 on the BSE. The scrip opened at Rs. 389.00 and has touched a high and low of Rs. 393.75 and Rs. 388.80 respectively. So far 7361 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip ...
Glenmark rises on launching Sitagliptin and its FDCs for adults with Type 2 Diabetes in India
Glenmark rises on launching Sitagliptin and its FDCs for adults with Type 2 Diabetes in India
Source: Accord Fintech
7/07/2022 2:15:27 PM
Glenmark Pharma trades higher as its arm acquires approved ANDAs for OTC portfolio from Wockhardt Glenmark Pharmaceuticals is currently trading at Rs. 386.95, up by 0.50 points or 0.13% from its previous closing of Rs. 386.45 on the BSE. The scrip opened at Rs. 385.00 and has touched a high and low of Rs. 387.55 and Rs. 379.15 respectively. So far 19602 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 348.90 on 20-Jun-2022. Last one week high and low of the scrip...
Glenmark Pharma trades higher as its arm acquires approved ANDAs for OTC portfolio from Wockhardt
Glenmark Pharma trades higher as its arm acquires approved ANDAs for OTC portfolio from Wockhardt
Source: Accord Fintech
28/06/2022 3:14:54 PM
Glenmark Pharma launches FDC drug for asthma in India The pharmaceutical company on Thursday announced that it has launched Indacaterol + Mometasone fixed-dose combination (FDC) drug for patients suffering from uncontrolled asthma in India. The FDC will help in the management of uncontrolled asthma by improving lung function, better symptom control, and reducing exacerbations. Launched under the brand name Indamet, the drug will increase the accessibility of quality drugs for effective asthma management. Glenmark is the first company in India to...
Glenmark Pharma launches FDC drug for asthma in India
Glenmark Pharma launches FDC drug for asthma in India
Source: Dion Global Solutions Ltd
16/06/2022 12:30:26 PM
Stock Picks - NTPC Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct NPTC Ltd Buy NTPC Ltd @157.00-158.00 CMP 157.75 Stop Loss 155.90 Target 159.30/160.50   Glenmark Pharmaceuticals Ltd Sell Glenmark Pharmaceuticals Ltd @ 382.00-383.00 CMP 380.85 Stop Loss 385.5 Target 379.20/3376.00   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Above views are of the author and not o...
Stock Picks - NTPC Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct
Stock Picks - NTPC Ltd and Glenmark Pharmaceuticals Ltd By ICICI Direct
Source: ICICI Direct
8/06/2022 11:17:24 AM
Buy Glenmark Pharmaceuticals Ltd For Target Rs.636 - Sushil Finance Glenmark Pharma Ltd. recently announced its performance for the quarter ended March 31, 2022. Following are the key highlights Highlights from the Quarter (Q4 FY22) Consolidated sales for the quarter were at Rs.3,019.1 cr recording a growth of about 5.6% yoy, with a 7%/17.6% growth in India and Europe business respectively. As per Jan-March '22 IQVIA data, the non-COVID based portfolio of the company grew 15.5% yoy as compared to the non-COVID IPM growth of 10.6% during the quarter....
Buy Glenmark Pharmaceuticals Ltd For Target Rs.636 - Sushil Finance
Buy Glenmark Pharmaceuticals Ltd For Target Rs.636 - Sushil Finance
Source: Sushil Finance Ltd
2/06/2022 11:36:21 AM
Neutral GSK Pharma Ltd Rs.1,570 - Motilal Oswal Muted 4QFY22; focus remains on key brands to revitalize growth Slower offtake witnessed in the Vaccine segment * GLXO delivered a lower-than-expected performance in 4QFY22. Subdued YoY growth in sales and higher raw material cost affected profitability. * We lower our FY23/FY24 EPS estimate by 4% each, factoring in a gradual recovery in Vaccines and elevated operating costs. We expect 11% earnings CAGR over FY22-24, adjusting for the tax provisions for promotional expenses of earlier...
Neutral GSK Pharma Ltd Rs.1,570 - Motilal Oswal
Neutral GSK Pharma Ltd Rs.1,570 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
21/05/2022 11:24:52 AM
Glenmark Pharma shines as its arm gets USFDA’s final approval for Abiraterone Acetate Tablets Glenmark Pharmaceuticals is currently trading at Rs. 400.15, up by 7.65 points or 1.95% from its previous closing of Rs. 392.50 on the BSE. The scrip opened at Rs. 397.50 and has touched a high and low of Rs. 400.15 and Rs. 397.50 respectively. So far 2675 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 386.30 on 12-May-2022. Last one week high and low of the scrip ...
Glenmark Pharma shines as its arm gets USFDA’s final approval for Abiraterone Acetate Tablets
Glenmark Pharma shines as its arm gets USFDA’s final approval for Abiraterone Acetate Tablets
Source: Accord Fintech
20/05/2022 9:39:01 AM
Glenmark gains as its arm gets tentative nod for Calcipotriene and Betamethasone Dipropionate Foam Glenmark Pharmaceuticals is currently trading at Rs. 414.90, up by 4.15 points or 1.01% from its previous closing of Rs. 410.75 on the BSE. The scrip opened at Rs. 412.90 and has touched a high and low of Rs. 418.75 and Rs. 404.30 respectively. So far 58848 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 405.40 on 06-May-2022. Last one week high and low of the scrip...
Glenmark gains as its arm gets tentative nod for Calcipotriene and Betamethasone Dipropionate Foam
Glenmark gains as its arm gets tentative nod for Calcipotriene and Betamethasone Dipropionate Foam
Source: Accord Fintech
9/05/2022 3:37:22 PM
Glenmark Pharma gains as its arm gets DCGI nod to conduct Phase 1 Clinical Trial of Novel Molecule GRC 54276 Glenmark Pharmaceuticals is currently trading at Rs. 483.05, up by 3.85 points or 0.80% from its previous closing of Rs. 479.20 on the BSE. The scrip opened at Rs. 483.80 and has touched a high and low of Rs. 485.20 and Rs. 478.05 respectively. So far 11706 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 415.60 on 07-Mar-2022. Last one week high and low of the scrip...
Glenmark Pharma gains as its arm gets DCGI nod to conduct Phase 1 Clinical Trial of Novel Molecule GRC 54276
Glenmark Pharma gains as its arm gets DCGI nod to conduct Phase 1 Clinical Trial of Novel Molecule GRC 54276
Source: Accord Fintech
11/04/2022 9:57:52 AM
Stock Picks - Bharti Airtel & Glenmark Pharmaceuticals Ltd By ICICI Direct Bharti Airtel Buy Bharti Airtel @755.00-757.00 CMP 756.00 Stop Loss 746.40 Target 770.90   Glenmark Pharmaceuticals Buy Glenmark Pharmaceuticals @ 444-446 CMP 444.70 Stop Loss 449.70 Target 436.20   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all participants are ...
Stock Picks - Bharti Airtel & Glenmark Pharmaceuticals Ltd By ICICI Direct
Stock Picks - Bharti Airtel & Glenmark Pharmaceuticals Ltd By ICICI Direct
Source: ICICI Direct
1/04/2022 11:15:47 AM
Glenmark Pharmaceuticals gains on raising sustainability-linked loan of $228 million Glenmark Pharmaceuticals is currently trading at Rs. 456.05, up by 5.95 points or 1.32% from its previous closing of Rs. 450.10 on the BSE. The scrip opened at Rs. 453.00 and has touched a high and low of Rs. 461.00 and Rs. 453.00 respectively. So far 40563 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 415.60 on 07-Mar-2022. Last one week high and low of the scrip...
Glenmark Pharmaceuticals gains on raising sustainability-linked loan of $228 million
Glenmark Pharmaceuticals gains on raising sustainability-linked loan of $228 million
Source: Accord Fintech
23/03/2022 12:28:01 PM
Glenmark Pharma soars as its arm receives USFDA’s approval for Lacosamide Tablets Glenmark Pharmaceuticals is currently trading at Rs. 454.35, up by 10.45 points or 2.35% from its previous closing of Rs. 443.90 on the BSE. The scrip opened at Rs. 445.00 and has touched a high and low of Rs. 457.85 and Rs. 445.00 respectively. So far 42623 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 690.60 on 19-Jul-2021 and a 52 week low of Rs. 415.60 on 07-Mar-2022. Last one week high and low of the scri...
Glenmark Pharma soars as its arm receives USFDA’s approval for Lacosamide Tablets
Glenmark Pharma soars as its arm receives USFDA’s approval for Lacosamide Tablets
Source: Accord Fintech
21/03/2022 10:38:50 AM